GlassScriptPhysician profile
Nalini Prasad
NPI 1881787679
$14,464.83
in general payments reported to CMS, 2019-2025
52 companies · $3,845 in 2025
The $3,845 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $702 · 2021: $1,075 · 2022: $2,248 · 2023: $2,551 · 2024: $3,381 · 2025: $3,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,760 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,760.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.27 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $1,149.89 | 2019-2025 | Crexont, Rytary, Ongentys |
| Lundbeck LLC | $1,053.64 | 2022-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $993.94 | 2022-2024 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $727.78 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Mdd US Operations, LLC | $712.18 | 2019-2025 | Apokyn, Apokyn, Gocovri |
| Axsome Therapeutics, INC. | $595.57 | 2024-2025 | Symbravo, Sunosi, Auvelity |
| Otsuka America Pharmaceutical, INC. | $576.68 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $533.84 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $516.37 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $473.91 | 2022-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $445.59 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $396.01 | 2019-2022 | |
| Biogen, INC. | $319.39 | 2021-2025 | Vumerity |
| Impel Pharmaceuticals INC. | $314.45 | 2022-2023 | Trudhesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalini Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.